Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A607801-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $399.90 | |
A607801-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $649.90 | |
A607801-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,299.90 | |
A607801-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,099.90 | |
A607801-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,339.90 |
Synonyms | example 4 [US20120122911] | MS-30639 | SCHEMBL4570348 | (3'S)-1',2',5,7-Tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxospiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carbo |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Calcitonin gene-related peptide type 1 receptor antagonist |
ALogP | 3.4 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide |
---|---|
INCHI | InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1 |
InChi Key | QIVUCLWGARAQIO-OLIXTKCUSA-N |
Canonical SMILES | O=C(c1cnc2c(c1)C[C@@]1(C2)C(=O)Nc2c1cccn2)N[C@H]1C[C@H]([C@H](N(C1=O)CC(F)(F)F)C)c1c(F)ccc(c1F)F |
Isomeric SMILES | C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F |
PubChem CID | 72163100 |
Molecular Weight | 603.52 |
CAS Registry No. | 1374248-81-3 |
---|---|
PubChem CID | 72163100 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2409021 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409022 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409023 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409024 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409025 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409026 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409027 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409029 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409031 | Certificate of Analysis | Oct 23, 2024 | A607801 |
L2409032 | Certificate of Analysis | Oct 23, 2024 | A607801 |
Starting at $1,668.90
Starting at $152.90
Starting at $1,334.90
Starting at $29.90
Starting at $699.90
Starting at $550.90
Starting at $1,668.90
Starting at $1,668.90
Starting at $1,668.90
Starting at $117.90
Starting at $171.90
1. Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L et al.. (2021) Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.. Cephalalgia, 71 (13): (3331024211042385). [PMID:34521260] [10.1021/op500134e] |